NCT05431582 is a Phase 1 clinical trial of ZN-c3 in Tumors, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT05431582?

NCT05431582 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT05431582?

Interventions in NCT05431582: ZN-c3, Bevacizumab, Pembrolizumab.

What condition does NCT05431582 study?

NCT05431582 studies Tumors, Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer.

Is NCT05431582 still recruiting?

NCT05431582 is currently withdrawn. Last updated 15 June 2023.

Last reviewed 2023-06-15 · How we verify

NCT05431582

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

Withdrawn Phase 1 Last updated 15 June 2023

What this trial tests

Phase 1 trial testing ZN-c3 in Tumors. Withdrawn.

Timeline

14 December 2022

Primary endpoint
14 December 2022

14 December 2022

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	14 December 2022
Primary completion	14 December 2022
Estimated completion	14 December 2022

Drugs / interventions tested

ZN-c3 (zn-c3) — full drug profile →
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
Pembrolizumab (pembrolizumab) — full drug profile →

Conditions studied

Tumors — all drugs for Tumors →
Ovarian Cancer — all drugs for Ovarian Cancer →
Breast Cancer — all drugs for Breast Cancer →
Lung Cancer — all drugs for Lung Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Tumors or Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Primary Objectives are to determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of ZN-c3 and ZN-c3 and bevacizumab or ZN-c3 and bevacizumab plus pembrolizumab in metastatic CCNE1 amplified and TP53 mutant solid tumors as well to evaluate antitumor activity of ZN-c3 and bevacizumab or ZN-c3 and bevacizumab plus pembrolizumab in metastatic CCNE1 amplified and TP53 mutant solid tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting the DNA damage response for cancer therapy.
Curtin NJ. · · 2023 · cited 30× · PMID 36606678 · DOI 10.1042/bst20220681
Combination, Modulation and Interplay of Modern Radiotherapy with the Tumor Microenvironment and Targeted Therapies in Pancreatic Cancer: Which Candidates to Boost Radiotherapy?
Benkhaled S, Peters C, Jullian N, Arsenijevic T, et al · · 2023 · cited 19× · PMID 36765726 · DOI 10.3390/cancers15030768
Synthetic and Medicinal Chemistry Approaches Toward WEE1 Kinase Inhibitors and Its Degraders.
Alli VJ, Yadav P, Suresh V, Jadav SS. · · 2023 · cited 18× · PMID 37323408 · DOI 10.1021/acsomega.3c01558
Advancing cancer therapy: new frontiers in targeting DNA damage response.
Qian J, Liao G, Chen M, Peng RW, et al · · 2024 · cited 16× · PMID 39372203 · DOI 10.3389/fphar.2024.1474337
The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies.
Melaiu O, Vanni G, Portarena I, Pistolese CA, et al · · 2023 · cited 14× · PMID 36834641 · DOI 10.3390/ijms24043226
Targeting the DNA damage response in cancer.
Federica G, Michela C, Giovanna D. · · 2024 · cited 12× · PMID 39492835 · DOI 10.1002/mco2.788
Exploiting DNA Replication Stress as a Therapeutic Strategy for Breast Cancer.
Zhang J, Chan DW, Lin SY. · · 2022 · cited 12× · PMID 36359297 · DOI 10.3390/biomedicines10112775
Targeting WEE1 Kinase in Gynecological Malignancies.
Zhang W, Li Q, Yin R. · · 2024 · cited 8× · PMID 38915863 · DOI 10.2147/dddt.s462056

Verify or expand the search:

Other trials of ZN-c3

Trials testing the same drug.

NCT05743036 — ZN-c3 in Adult Participants With Metastatic Colorectal Cancer · Phase 1 · terminated
NCT05682170 — Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) · Phase 1, PHASE2 · terminated
NCT04972422 — A Phase 1b Study of ZN-c3 in Chinese Subjects · Phase 1 · unknown

Other recruiting trials for Tumors

Currently open trials in the same condition.

NCT05697406 — HP Pyruvate MRI in Cancers · Phase 1, PHASE2 · recruiting
NCT05103358 — Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 G · Phase 2 · active not recruiting
NCT05103969 — Cohort of Tumors With POLE/D1 Mutation · recruiting
NCT04950959 — XACT ACE Observational Registry · recruiting
NCT04341181 — ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling · Phase 2 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05431582 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 15 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05431582.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing